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The beta score, a composite measure of beta cell func-
tion after islet transplantation, has limited sensitivity
because of its categorical nature and requires a mixed-
meal tolerance test (MMTT). We developed a novel
score based on a single fasting blood sample. The
BETA-2 score used stepwise forward linear regression
incorporating glucose (in millimoles per liter), C-pep-
tide (in nanomoles per liter), hemoglobin A1c (as a per-
centage) and insulin dose (U/kg per day) as continuous
variables from the original beta score data set (n = 183
MMTTs). Primary and secondary analyses assessed the
score’s ability to detect glucose intolerance (90-min
MMTT glucose ≥8 mmol/L) and insulin independence,
respectively. A validation cohort of islet transplant
recipients (n = 114 MMTTs) examined 12 mo after
transplantation was used to compare the score’s abil-
ity to detect these outcomes. The BETA-2 score was
expressed as follows (range 0–42):
BETA-2 score¼
 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
fasting C-peptide (nmol/L)
p
ð1 –insulin dose [units/kg])
!
Fasting plasma glucose (mmol/L)
HbA1cð%Þ
1000
A score <20 and ≥15 detected glucose intolerance and
insulin independence, respectively, with >82% sensi-
tivity and specificity. The BETA-2 score demonstrated
greater discrimination than the beta score for these
outcomes (p < 0.05). Using a fasting blood sample, the
BETA-2 score estimates graft function as a continuous
variable and shows greater discrimination of glucose
intolerance and insulin independence after transplan-
tation versus the beta score, allowing frequent assess-
ments of graft function. Studies examining its utility
to track long-term graft function are required.
Abbreviations: AIR, acute insulin response; AUROC,
area under the receiver operating characteristic; CI,
confidence interval; HbA1c, hemoglobin A1c; IE, islet-
equivalent units; IQR, interquartile range; ITx, islet
transplantation; MMTT, mixed-meal tolerance test;
OGTT, oral glucose tolerance test; ROC, receiver
operating characteristic; SEM, standard error of the
mean; SUITO, secretory unit of islet transplant
objects; WHO, World Health Organization
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Introduction
Islet transplantation (ITx) is indicated in patients with type
1 diabetes and frequent severe hypoglycemia (1–5). ITx
can achieve short-term insulin independence in almost all
cases, and it is recognized that the islet mass transplanted
and primary graft function after transplantation are impor-
tant for long-term islet graft success (6,7). Despite improv-
ing results, insulin independence rates (approaching 50%
at 5 years) fall short of a cure for type 1 diabetes (2,6,8).
There is growing consensus that the success of ITx should
not be defined by the presence or absence of insulin inde-
pendence but rather by maintenance of stable glycemic
control and protection from severe hypoglycemia (2,4,9).
This protection can be maintained with relatively low levels
of endogenous insulin production compared with the
degree of graft function required for insulin independence
(1,10). Patients without residual graft function (C-peptide
negative) are at high risk for recurrent severe hypoglycemia
(Collaborative Islet Transplant Registry data (6)); therefore,
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graft function after transplant should be thought of as a
continuum.
Assessment of graft function, like the assessment of
beta cell mass in diabetes (11,12), is complex. The most
precise tools rely on complex metabolic tests measuring
insulin secretion in response to various stimuli (1,13–15),
and they are time consuming, expensive and likely to be
used only in a research setting. Because they cannot be
performed routinely on a frequent basis, it is hard to
accurately track changes in graft function over time.
The use of simple estimates of beta cell mass in ITx
recipients based on fasting glucose and C-peptide levels
(e.g. C-peptide:glucose ratio (16), secretory unit of islet
transplant objects [SUITO] index (17)) may be con-
founded by the use of exogenous insulin or poor glyce-
mia. The best validated tool currently is the beta score
(18). This tool integrates fasting glucose and a stimulated
C-peptide level 90 min after a mixed-meal tolerance test
(MMTT) with hemoglobin A1c (HbA1c) and use of insulin
or glucose-lowering therapies.
Each component of the score is assigned a categorical
score of 0, 1, or 2 (Table S1), with a maximum score of
8 representing excellent graft function and a score of 0
representing no residual graft function. The score has
been independently validated using continuous glucose-
monitoring systems, with scores ≥7 required to maintain
euglycemia, but protection from severe hypoglycemia by
ITx can be achieved with a score ≥3 (10).
The categorical nature of the beta score (which reduces
the information gained from each individual variable) and
the relative infrequency of MMTT testing means that the
beta score does not identify subtle early changes in
transplant function. The weighting of each variable may
not be optimal because changes in treatment can result
in spurious improvements in beta score. Deteriorating
graft function, for example, treated by adding insulin (1
point) to reduce fasting plasma glucose (+1 or +2 points)
and HbA1c (+1 point) would yield an improved, although
spurious, beta score.
Stimulated C-peptide is a widely used measure of
endogenous beta cell function in both ITx and immuno-
therapy trials in type 1 diabetes (19,20), but fasting
C-peptide correlates very well with stimulated measures
(18,20). Fasting C-peptide can be tested frequently and
at lower cost than following an MMTT.
Because the natural history of the progressive decline in
graft function seen in many islet recipients over time is
poorly understood, we sought to develop and validate a
simple clinical tool to assess beta cell function using a
single fasting blood sample factoring in the dose of insu-
lin required per day and the patient’s body weight. Such
a score in which each variable is expressed continuously
may more accurately describe the spectrum of islet graft
function and be more sensitive to detect changes in
graft function over time. This could be used to assess
graft function at regular outpatient visits and not just at
6- to 12-mo intervals, with benefits in cost savings and
ease and convenience for the patient.
Research Design and Methods
Derivation cohort
Overall, 57 participants with type 1 diabetes and normal renal function
from the originally described Edmonton cohort transplanted before
the year 2005 (data shown as mean plus or minus standard error of
the mean [SEM]; age 42.1  1.3 years, duration of diabetes
26.1  11.3 years) had 183 MMTTs after transplant at 3, 6, 12, 18, and
24 mo and then yearly up to 5 years (18). The induction agents and main-
tenance immunosuppression are shown (Table S2).
In this original cohort, participants underwent intravenous glucose toler-
ance and intravenous arginine tests (79 and 39 tests, respectively) at the
above time points, and the acute insulin responses (AIRs) to glucose and
arginine, respectively, were derived.
The AIRs to glucose and arginine have been shown to be highly predic-
tive of beta cell secretory capacity and can provide estimates of func-
tional islet beta cell mass in ITx recipients (21). AIRs to glucose and
arginine were calculated, as described previously (1).
A composite BETA-2 score was derived based on a single fasting blood
sample and insulin use standardized to body weight (units per kilogram
of body weight). Insulin dose, HbA1c, and fasting C-peptide and glucose
were individually fitted to the 90-min glucose level following a standard
MMTT (360 ml Ensure HP; Abbott Laboratories, Saint-Laurent, Que´bec,
Canada) using appropriate transformations, as detailed in the statistical
methods, before being combined in a total score. The association
between the BETA-2 score and other engraftment indices was exam-
ined.
Although glucose tolerance is defined by the 75-g oral glucose tolerance
test (OGTT), MMTTs are performed more commonly after ITx. In our pri-
mary analysis, the BETA-2 score was derived and best detected abnor-
mal glucose tolerance during the MMTT, with maximum sensitivity and
specificity (described under Statistical analyses). We defined abnormal
glucose tolerance as a 90-min MMTT glucose level ≥8 mmol/L, based on
a previous study of ITx recipients undergoing simultaneous 75-g OGTTs
and MMTTs (22). In this study, the 90-min MMTT glucose level
≥8 mmol/L was superior to the fasting glucose level derived from the
MMTT for diagnosing diabetes (World Health Organization [WHO] criteria:
after 75-g OGTT, fasting plasma glucose level ≥7 mmol/L or 2-h glucose
level ≥11.1 mmol/L) with sensitivity and specificity of 91% and 87.5%,
respectively (22). The finding is consistent with other studies examining
ITx recipients. A longitudinal study comparing recipients who remained
insulin independent over an 18-mo period with those who recommenced
insulin found that 90-min MMTT glucose was an earlier marker of graft
dysfunction than fasting plasma glucose, reflecting loss of first-phase
insulin secretion (23). Studies comparing MMTTs with OGTTs in patients
with a range of glucose intolerance demonstrated 30% lower glucose
excursions with MMTTs at equivalent time points following caloric inges-
tion, again consistent with our data (24,25). We reasoned that because
this level of glucose intolerance is associated with morbidity and mortality
(26–28), intervention with exogenous insulin may be initiated, reinforcing
this as a clinically relevant outcome variable.
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Independence from exogenous insulin (with HbA1c <6.5%) is important
clinically; therefore, we also examined the BETA-2 and beta scores in
relation to this clinical outcome (described under Statistical analyses).
Validation cohort
To validate the BETA-2 score, we used retrospective data from MMTTs
performed at 12 mo (8  0.5 mo after last infusion) in a group of ITx
recipients receiving their first ITx after the year 2006, selected to repre-
sent a broad spectrum of graft function (n = 114; 109 ITx-alone and five
islet-after-kidney recipients, all with normal renal function; mean age
49.0  0.9 years and duration of diabetes 31.5  1.0 years). Table S2
shows induction agents and maintenance immunosuppression.
Scores were not calculated for participants using exogenous insulin
whose fasting plasma glucose values were ≤3.5 mmol/L because of the
anticipated suppression of C-peptide production (18).
Case study following ITx
Data from a man aged 25 years with type 1 diabetes since age 12 years
who received two islet infusions (478 851 islet-equivalent units
[IE] = 6031 IE/kg and 364 601 IE = 5043 IE/kg) 11 months apart are pre-
sented to demonstrate and compare the utility of the BETA-2 score with
the beta score. MMTTs were performed 4 weeks after each islet infusion.
Following the initial transplant, the patient’s insulin requirements fell to
40% of baseline but increased steadily, and he was noted to be
C-peptide negative at day 75 after the first transplant. A second trans-
plant 11 mo later led to a substantial reduction in insulin requirements ini-
tially but was not maintained, and graft function was lost within 2 mo
after the second transplant.
Metabolic studies
The methods for the metabolic studies (MMTT, intravenous glucose toler-
ance test, arginine stimulation test) have been described previously
(2,18). Body weight and insulin use (average insulin dose per day over
the previous 7 days divided by body weight in kilograms) were extracted
from medical records.
Biochemical assays were measured in duplicate. Plasma glucose concen-
trations were determined by the glucose oxidation method. C-peptide
concentrations were measured using commercial kits (Roche Elecsys;
Roche Diagnostics, Indianapolis, IN; lower limit of sensitivity of the
C-peptide assay was 0.1 nmol/L before 2005 (18) and 0.02 nmol/L after
2005; assay equivalence confirmed, Pearson R2 = 0.99).
Ethics approval
Participants provided written informed consent, and the study was
approved by the University of Alberta Health Research Ethics Board and
conducted in accordance with the principles endorsed by the Declaration
of Helsinki.
Statistical analyses and validation of BETA-2 score
Statistical analyses were performed using Stata version 12 (StataCorp,
College Station, TX). Descriptive statistics are expressed as mean  SEM
and median (interquartile range [IQR]) as appropriate. Data were tested
for normality, and Pearson or Spearman rank correlation coefficients were
determined, as appropriate.
A composite BETA-2 score was derived from the original cohort of partici-
pants in Edmonton and was based on the following independent vari-
ables: fasting plasma glucose, fasting C-peptide values, HbA1c
(percentage) and insulin use. Univariate regression analyses of each of
these variables with stimulated glucose (1) was performed, and
transformations were applied as appropriate to normalize the residuals,
followed by stepwise forward multiple linear regression analyses (18). In
the derivation cohort, receiver operating characteristic (ROC) curves were
constructed for participants’ BETA-2 scores based (i) on the 90-min
MMTT glucose level ≥8 mmol/L (which has been shown to correlate
closely with a diagnosis of diabetes [WHO criteria] during the OGTT (22))
and (ii) on insulin independence with HbA1c <6.5%, and then the discrim-
ination and predictive accuracy of the score was determined.
The score that best detected these outcome variables with maximum
sensitivity and specificity was derived (29).
In the validation cohort, ROC curves were constructed for participants’
BETA-2 and beta scores based on the 90-min MMTT glucose level
≥8 mmol/L and insulin independence with HbA1c <6.5%. The area under
the ROC (AUROC) curves were compared to determine whether the
BETA-2 score detected the outcome variables with greater discrimination
than the beta score. Statistical significance was set at 5%.
Results
In the derivation cohort, a total of 183 of the 187 MMTTs
were eligible for analysis (18). Four MMTTs were
excluded because fasting plasma glucose concentrations
were <3.5 mmol/L. Overall, 70 of the 183 MMTTs were
associated with insulin use (38% MMTTs; 33 partici-
pants), and 69% (n = 126) of MMTTs had 90-min glu-
cose levels ≥8 mmol/L.
In the validation study, no participants were excluded
because of hypoglycemia prior to meal testing. More-
over, 76 of 114 participants (66%) had 90-min glucose
levels ≥8 mmol/L, and 72 of 114 participants (63%) were
using exogenous insulin.
Formulation of BETA-2 score in the derivation cohort
The metabolic variables fasting plasma glucose (in mil-
limoles per liter), HbA1c (as a percentage), fasting
C-peptide (in nanomoles per liter) and insulin dose (units
per kilogram of body weight) from the original cohort
study with 183 complete MMTTs were examined.
Median fasting plasma glucose was 6.4 mmol/L (IQR
5.7–7.9 mmol/L), HbA1c was 6.1% (IQR 5.7–6.6%; med-
ian 43 mmol/mol [IQR 39–49 mmol/mol]), and stimulated
glucose was 10.2 mmol/L (IQR 7.3–13.4 mmol/L).
Fasting plasma glucose and HbA1c were independently
associated with the 90-min glucose level after MMTT
(p < 0.0001) (Figure S1).
Stimulated and fasting C-peptide concentrations were
closely associated: 1.28 nmol/L (IQR 0.88–1.74 nmol/L)
and 0.61 nmol/L (IQR 0.39–0.88 nmol/L), respectively
(r = 0.78, p < 0.001). In nine MMTTs, neither the stimu-
lated nor the corresponding fasting C-peptide concentra-
tions were detected. In nine MMTTs, stimulated
C-peptide concentrations were detected, but fasting
C-peptide concentrations were below the level of assay
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detection (0.1 nmol/L). Fasting C-peptide concentrations
transformed using a square root function demonstrated
the closest association with graft function (p < 0.0001)
(Figure S1).
The range of insulin doses taken by participants was
0–0.91 U/kg per day. The insulin dose subtracted from
unity demonstrated the closest association with the
90-min glucose level after MMTT (p < 0.0001) (Figure S1).
The BETA-2 score was generated as follows:
BETA-2 score¼
 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
fasting C-peptide (nmol/L)
p
ð1 –insulin dose [units/kg])
!
Fasting plasma glucose (mmol/L)
HbA1cð%Þ
1000
Multiplication by 1000 converted the score to a range
from 0 to 42 in the derivation cohort.
BETA-2 score and islet engraftment
The BETA-2 score was associated with the 90-min glu-
cose level after MMTT, the beta score and the AIR after
intravenous glucose and arginine (all p < 0.0001) (Fig-
ure 1). The relationship between the beta score intervals
(beta score 0–2, 3–4, 5–6 and 7–8) and the BETA-2 score
were closely associated (r = 0.99; p < 0.001) (Figure 2).
BETA-2 score and detection of 90-min MMTT glucose
level ≥8 mmol/L and insulin independence (HbA1c
<6.5%) after ITx
The BETA-2 score in participants with 90-min MMTT glu-
cose levels ≥8 mmol/L was two times lower than in their
counterparts (13 [IQR 5–18] vs. 26 [IQR 22–29];
p < 0.001).
The BETA-2 score in insulin-dependent participants was
lower than in insulin-independent (HbA1c <6.5%) partici-
pants (7 [IQR 2–12] vs. 23 [IQR 18–27]; p < 0.001). This
was also the case when only participants with HbA1c
<6.5% were analyzed: BETA-2 scores were 9 (IQR 5–14)
r=-0.73; 
p<0.0001
r=0.82; 
p<0.0001 
r=0.72; 
p<0.0001 
r=0.59; 
p<0.0001 
BA
C D
Figure 1: Relationship between BETA-2 score and indices of graft function. Relationship between BETA-2 score and indices of
graft function: (A) stimulated glucose, (B) beta score and acute insulin response (C) to glucose and (D) to arginine were highly statisti-
cally significant (all p < 0.01). AIR, acute insulin response.
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versus 25 (IQR 20–29) (p < 0.001; 19% and 48% of
MMTTs, respectively, in the derivation cohort).
The AUROC curve analyses demonstrated excellent
discrimination between MMTT glucose level ≥8 versus
<8 mmol/L and insulin independence versus dependence
(AUROC 86  2% and 96  1%, respectively; all
p < 0.001) (Figure 3). A BETA-2 score <20 had sensitivity
of 82% (95% confidence interval [CI] 74–88%) and speci-
ficity of 82% (95% CI 70–91%) for detecting a 90-min
MMTT glucose level ≥8 mmol/L after ITx, with a positive
predictive value of 91% and a negative predictive value
of 68%. A BETA-2 score ≥15 had sensitivity of 89%
(95% CI 82–94%) and specificity of 88% (95% CI 78–94%)
with a positive predictive value of 98% and a negative
predictive value of 99.5% for predicting insulin indepen-
dence after ITx.
Validation of BETA-2 score in separate cohort
In total, 112 participants in the validation cohort had mea-
surable stimulated and fasting C-peptide concentrations
(1.18 nmol/L [IQR 0.59–1.77 nmol/L] and 0.53 nmol/L
[IQR 0.24–0.76 nmol/L], respectively), whereas two par-
ticipants had nondetectable concentrations for both stim-
ulated and fasting C-peptide. Fasting plasma glucose
was 6.8 mmol/L (IQR 5.8–9.2 mmol/L), HbA1c was 6.5%
(IQR 6.0–7.2%; 48 mmol/mol [IQR 42–54 mmol/mol]),
stimulated glucose was 10.4 mmol/L (IQR 7.0–15.9
mmol/L), and the insulin dose range was 0–0.64 U/kg per
day.
The BETA-2 score demonstrated a range similar to the
derivation cohort (IQR 0–38) with approximately threefold
lower scores in participants with a 90-min MMTT glu-
cose level ≥8 vs. <8 mmol/L after ITx (8 [IQR 3–13] vs.
24 [IQR 19–28]; insulin-dependent vs. -independent par-
ticipants: 7 [IQR 3–12] vs. 25 [IQR 20–28]; all
p < 0.0001). The BETA-2 scores in insulin-independent
(HbA1c <6.5%) participants were significantly greater
than in those on insulin with HbA1c <6.5% (26 [IQR 22–28]
vs. 12 [IQR 9–17]; p < 0.0001).
A 90-min MMTT glucose level ≥8 mmol/L and insulin
independence were better discriminated with the
BETA-2 score than the beta score (AUROC for 90-min
MMTT glucose level ≥8 mmol/L was 91  2% vs.
86  3% and for insulin independence was 96  1%
vs. 90  1%; ROC comparison of BETA-2 vs. beta score,
p = 0.04 and p = 0.03, respectively) (Figure 3).
The BETA-2 score showed a better ability to discriminate
between participants’ 90-min MMTT glucose levels
≥8 versus <8 mmol/L and insulin independence: The
number of participants with nondiscriminating scores
was significantly lower for the BETA-2 score than for the
beta score (55 vs. 89 and 61 vs. 72 participants had over-
lapping scores in the two groups; both p < 0.0001) (Fig-
ure 4).
Illustration of clinical utility of the BETA-2 score
In the case study, the participant underwent two ITxs
(Figure 5). Following the first ITx, the BETA-2 score indi-
cated deteriorating graft function beginning on day 15,
whereas the beta score could not be calculated until the
MMTT at 4 weeks. Immediately following the second
transplant, there was a rapid decline in the BETA-2
score, which was close to 0 by the time of the MMTT at
4 weeks after transplant. The beta score was 3 on both
occasions.
Discussion
The BETA-2 score derived from fasting C-peptide, fasting
plasma glucose, HbA1c and insulin dose expressed as con-
tinuous variables, is an improved measure of beta cell func-
tion following ITx and may be determined from a single
fasting blood sample and basic clinical measures. Impor-
tantly, because of the maximum use of information from
constituent variables, the score shows superiority to the
originally described beta score in its assessment of graft
function (18). In our primary analysis, a BETA-2 score <20
demonstrates excellent discrimination between those with
poor graft function who may require intensification of treat-
ment with additional islet infusions or exogenous insulin
therapy versus those with superior graft function who do
not require such intervention, with high sensitivity and
specificity. Similarly a BETA-2 score ≥15 discriminates
between those who are insulin independent (HbA1c
<6.5%) and those on or requiring insulin. We further
B
ET
A
-2
 s
co
re
Figure 2: Relationship between beta score intervals and the
BETA-2 score in the derivation cohort. The relationship
between the beta score intervals and the BETA-2 score were
closely associated in the derivation cohort as demonstrated
(r = 0.99; p < 0.01), with similar values in the validation cohort
(data not shown). Data are shown as median (interquartile
range).
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demonstrated proof of principle of the BETA-2 score’s abil-
ity to track graft function following ITx.
We tested the performance of the BETA-2 score to pre-
dict both glucose intolerance (90-min MMTT glucose
level <8 mmol/L) and insulin independence with HbA1c
<6.5%. This approach is more robust than testing only
for prediction of insulin independence because insulin
use is included in both predictor and outcome variables.
Although the OGTT is the gold standard to detect glu-
cose intolerance, we had not performed OGTTs system-
atically in either the derivation or validation cohorts.
Because the BETA-2 score uses a single fasting blood
sample, it is cheaper and easier to measure than the
beta score. In a recent review, the MMTT with basal and
stimulated samples cost approximately twice as much as
scoring systems that relied on fasting metabolites alone
(30,31). The ability to perform more frequent assess-
ments of graft function over time is another advantage
that may result in a greater likelihood of graft dysfunction
being detected with the potential to intervene.
Notably, when the original beta score study was pub-
lished in 2005 (18), the level of detection of C-peptide
concentrations was 0.1 nmol/L, whereas more sensitive
assays were used in the validation study. This may
explain why nine participants in the derivation cohort had
detectable C-peptide only after MMTT. In contrast, the
112 participants in the validation cohort who had
BETA-2 AUROC=86±2%*
B
C
BETA-2 AUROC=96±1%*
D
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Figure 3: BETA-2 score’s detection of 90-min MMTT glucose level ≥8 mmol/L and insulin independence following islet trans-
plantation in derivation and validation cohorts. (A) Participants in the original Edmonton derivation cohort (n = 58, 183 MMTTs),
with 90-min MMTT glucose levels ≥8 mmol/L (69% of cohort). The AUROC curve was 86  2%, reflecting excellent discrimination
(*p < 0.001) between the glycemic groups. A BETA-2 score <20 detected a 90-min MMTT glucose level ≥8 mmol/L with sensitivity of
82% (95% CI 74–88%) and specificity of 82% (95% CI 69–91%). (B) BETA-2 and beta scores for participants (n = 114) in the valida-
tion cohort with 90-min MMTT glucose levels ≥8 mmol/L (66% of cohort) versus <8 mmol/L confirmed the greater accuracy of the
BETA-2 score for detecting 90-min MMTT glucose levels ≥8 mmol/L (ROC comparison; ‡p = 0.04). (C) Participants in the derivation
cohort were segregated by insulin independence with HbA1c <6.5% (56% of cohort) versus insulin dependence. The AUROC curve
was 96.4  1.1%, reflecting excellent discrimination (*p < 0.001) between the groups. A BETA-2 score ≥15 predicted insulin indepen-
dence with sensitivity of 89% (95% CI 82–94%) and specificity of 88% (95% CI 78–94%). (D) BETA-2 and beta scores for participants
(n = 114) in the validation cohort with insulin independence (HbA1c <6.5%; 37% of cohort) versus insulin-dependent participants con-
firmed greater accuracy of the BETA-2 score for detecting insulin independence (ROC comparison; ‡p = 0.03). AUROC curve, area
under the receiver operator characteristic curve; CI, confidence interval; MMTT, mixed-meal tolerance test; ROC, receiver operator
characteristic.
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detectable C-peptide had it detected in both the fasting
and stimulated states. Given the wide use of sensitive
C-peptide assays (2), it is unlikely that failure to detect
fasting C-peptide will prevent calculation of the BETA-2
score in patients with functioning islet grafts. It is impor-
tant to interpret C-peptide in the context of blood glucose
concentrations. The BETA-2 score should not be calcu-
lated if the patient is hypoglycemic because this would
erroneously suggest no graft function when, in fact,
C-peptide is merely suppressed by exogenous insulin.
Our study includes the largest number of participants in
an islet function scoring system study published to date
(30,31). The other notable strength of the study is the
heterogeneity of the participants, including ITx-alone
and islet-after-kidney recipients who received a variety
of induction agents and maintenance immunotherapy
(6,7,32–34) and who represented a broad spectrum of
graft function.
The close correlation of the BETA-2 score with other
measures of graft function including the AIRs to glucose
and arginine (18) and with the beta score further corrobo-
rates the robustness of the scoring system.
Use of insulin is associated with graft dysfunction and
lower beta scores (18). A relative contraindication to ITx
is insulin resistance with pretransplant insulin require-
ments ≥0.9 U/kg of body weight. Our formula included
insulin subtracted from unity and may not be extrapo-
lated to situations in which the insulin dose is >1 U/kg;
this may be breached in auto-ITx and if indications for
cell transplant therapy are expanded to include higher
insulin users in the future. In these scenarios, further val-
idation studies will be necessary.
The utility of any scoring system depends on its ability to
detect clinically relevant scenarios. A beta score ≥3 is asso-
ciated with protection from hypoglycemia, ≥5 indicates
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Figure 4: Frequency of beta and BETA-2 scores according to 90-min MMTT glucose level ≥8 mmol/L and insulin indepen-
dence. Frequency of beta and BETA-2 scores in islet transplant recipients is demonstrated according to 90-min MMTT glucose level
≥8 or <8 mmol/L (A and B) and insulin dependence versus independence (C and D) in the validation cohort. The BETA-2 scores
demonstrated greater resolution than the beta scores (p < 0.001). MMTT, mixed-meal tolerance test.
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improved glycemic control and ≥7 indicates normalized gly-
cemic control and insulin independence (10). Similarly, a
SUITO index ≥26 can predict insulin independence with a
positive predictive value of 84% and a negative predictive
value of 89%, with values ≤10 representing poor graft func-
tion and intermediate values indicative of partial graft func-
tion (17). We confirmed that a BETA-2 score <20 detects
glucose intolerance (90-min MMTT glucose level ≥8 mmol/
L) with sensitivity and specificity of 82%. Importantly, the
BETA-2 score showed superiority over the beta score for
the detection of glucose intolerance, with greater disper-
sion of the BETA-2 scores versus the beta scores reflecting
better discrimination of poor versus good graft function.
Given that the BETA-2 score is an improved iteration of the
original score but uses all continuous data from the vari-
ables, it is highly likely that the BETA-2 score will relate at
least as well to hypoglycemia and continuous glucose-mon-
itoringmeasures, but this should be formally confirmed.
The BETA-2 score may be more sensitive to small
changes in graft function compared with the beta score
because it is based on continuous variables, and we
showed in the case study that graft function may be fol-
lowed more frequently and thus more closely compared
with the beta score with graft dysfunction identified ear-
lier. The increased discriminative power of the BETA-2
score compared with the beta score in ROC analysis,
despite the wider spread of BETA-2 scores, emphasizes
that it may reflect graft function with more resolution.
A disadvantage of the BETA-2 score is the somewhat
complicated calculation required compared with many
other scores (18); however, once the BETA-2 formula
has been entered into a simple spreadsheet, the
calculation may be iterated rapidly. The score has
already been integrated into our local clinical database
with ease, and we have developed a BETA-2 score
Web-based calculator (https://sites.google.com/a/islet.ca/
beta-2/). Calculation of the original beta score, which
required the categorization of four continuous variables,
can be laborious.
In addition, the BETA-2 score requires information on
insulin use and weight that is not required for other
scores, including SUITO (17), and C-peptide:glucose ratio
(16,31), which has been used (although generally not vali-
dated) in ITx. We believe that including insulin use is nec-
essary to assess beta cell function in groups containing
both insulin-independent and -dependent participants.
The inclusion of HbA1c avoids the potential bias that
could result if insulin were withheld to maintain “insulin
independence” but with hyperglycemia.
The BETA-2 score, unlike the beta score, does not con-
sider the use of oral hypoglycemic agents or noninsulin
antihyperglycemic agents. Although insulin was preferred
previously because of adverse effects of antihyper-
glycemics (side effects, metabolic burnout, potential drug
interactions [unpublished observations]), newer therapies
(dipeptidyl peptidase 4 inhibitors) are well tolerated (35).
The use of antidiabetic drugs may serve to either
increase or decrease the BETA-2 score, although it is
difficult to predict the magnitude of change. Further stud-
ies are needed to validate the score in these circum-
stances.
Although developed and validated in ITx as a tool to esti-
mate graft function and to predict insulin independence,
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Figure 5: Example of beta versus BETA-2 scores in a participant after islet transplantation. The beta score and the BETA-2
score were demonstrated for a participant with type 1 diabetes receiving two islet infusions 11 mo apart. MMTTs were performed
1 mo following each transplant. Fasting blood samples were measured frequently, allowing frequent calculation of the BETA-2 score,
whereas the participant could attend MMTTs only infrequently; therefore, the beta score was calculated for the first time at 4 weeks
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the BETA-2 score has a number of potential applications
as an intermediate or surrogate outcome in ITx (e.g. in
clinical trials testing new strategies to enhance engraft-
ment and comparing strategies to prevent graft loss) and
may be used potentially in beta cell replacement from
emerging cell sources and pancreas transplantation. It
may also find utility beyond ITx for situations in which
regular monitoring of beta cell function is required, per-
haps in trials of beta cell preservation in new onset type
1 diabetes.
In summary, the BETA-2 score is a unique validated com-
posite score of beta cell function that incorporates the
continuous variables glucose, C-peptide, HbA1c and insu-
lin dose and that correlates strongly with other validated
measures of graft function. The score has the advantage
of being highly discriminatory, uses fasting variables only
and performs better at detecting abnormal glucose toler-
ance and insulin independence following ITx than the
original beta score. We demonstrated the clinical applica-
bility of this scoring system in tracking islet engraftment
over time, including its utility for the early detection of
graft dysfunction. Further longitudinal studies may focus
on its utility for predicting graft failure.
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